During this segment, the panelists discuss the how the trend toward outpatient care and development of disease-modifying therapies for the treatment of multiple sclerosis (MS) has affected costs of care.
 
Leslie Fish, PharmD, explains that because most treatment options for MS are available through the pharmaceutical side, the costs of medications and entire cost of treatment for MS has risen dramatically since 2010.
 
Gary M. Owens, MD, agrees and explains a 3 year analysis that compared the direct medical costs of MS to pharmaceutical costs and revealed that 85% of the expenditures for the treatment of MS result on the pharmaceutical side.
 
Dr Fish continues by explaining how the decrease in the number of hospitalizations is relative to the trend to treat MS in an outpatient care setting.
 
The panelists conclude the discussion with concerns that as the treatment costs for MS continue to rise, many aspects of treatment aren’t covered, which leaves a huge burden on patients, their caregivers, and family members.

Episode 7 - Increased Monetary Costs of Multiple Sclerosis

During this segment, the panelists discuss the how the trend toward outpatient care and development of disease-modifying therapies for the treatment of multiple sclerosis (MS) has affected costs of care.
Published Online: October 07, 2013
During this segment, the panelists discuss the how the trend toward outpatient care and development of disease-modifying therapies for the treatment of multiple sclerosis (MS) has affected costs of care.
 
Leslie Fish, PharmD, explains that because most treatment options for MS are available through the pharmaceutical side, the costs of medications and entire cost of treatment for MS has risen dramatically since 2010.
 
Gary M. Owens, MD, agrees and explains a 3 year analysis that compared the direct medical costs of MS to pharmaceutical costs and revealed that 85% of the expenditures for the treatment of MS result on the pharmaceutical side.
 
Dr Fish continues by explaining how the decrease in the number of hospitalizations is relative to the trend to treat MS in an outpatient care setting.
 
The panelists conclude the discussion with concerns that as the treatment costs for MS continue to rise, many aspects of treatment aren’t covered, which leaves a huge burden on patients, their caregivers, and family members.

View More From This Discussion
Episode 1 Episode 1 - The Changing Tides of Multiple Sclerosis: Where Do We Currently Stand?
Episode 2 Episode 2 - Elucidating the Patient's Starting Point in Care
Episode 3 Episode 3- Exploring the Etiology of Multiple Sclerosis
Episode 4 Episode 4- Characterizing Multiple Sclerosis
Episode 5 Episode 5 - Elucidating the Economic Burden of MS
Episode 6 Episode 6 - Discussing the Pathophysiology of MS
Episode 7 Episode 7 - Increased Monetary Costs of Multiple Sclerosis
Episode 8 Episode 8 - Long-Term Effects of Disease-Modifying Therapies
Episode 9 Episode 9 - Exploring Trials, Data, and the Future of Multiple Sclerosis
Episode 10 Episode 10 - Treatment Complexities
Episode 11 Episode 11 - Clinical Guidelines Vital to the Future of MS
Episode 12 Episode 12 - New MS Agents Challenged
Episode 13 Episode 13 - Treatment Challenges for Progressive Disease
Episode 14 Episode 14 - Concerns about Rising Costs of Treatment
Episode 15 Episode 15 - Controlling Drug Prices and Working at the Population Level
Episode 16 Episode 16 - MRI Scans and MS
Episode 17 Episode 17 - Conclusion: Treatment Advancements and Final Remarks
right-arrow
Related Articles

More on AJMC.COM

$vacMongoViewPlus$